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OBJECTIVE: This study was designed to evaluate the effects of terlipressin versus fluid resuscitation with normal saline, hyper-
tonic saline or hypertonic-hyperoncotic hydroxyethyl starch, on hemodynamics, metabolics, blood loss and short-term survival in 
hemorrhagic shock. 
METHOD: Twenty-nine pigs were subjected to severe liver injury and treated 30 min later with either: (1) 2 mg terlipressin in a 
bolus, (2) placebo-treated controls, (3) 4 mL/kg 7.5% hypertonic NaCl, (4) 4 mL/kg 7.2% hypertonic-hyperoncotic hydroxyethyl 
starch 200/0.5, or (5) normal saline at three times lost blood volume. 
RESULTS: The overall mortality rate was 69%. Blood loss was significantly higher in the hypertonic-hyperoncotic hydroxyethyl 
starch and normal saline groups than in the terlipressin, hypertonic NaCl and placebo-treated controls groups (p<0.005). Hyper-
kalemia (K>5 mmol/L) before any treatment occurred in 66% of the patients (80% among non-survivors vs. 22% among survivors, 
p=0.019). Post-resuscitation hyperkalemia occurred in 86.66% of non-survivors vs. 0% of survivors (p<0.001). Hyperkalemia was 
the first sign of an unsuccessful outcome for the usual resuscitative procedure and was not related to arterial acidemia. Successfully 
resuscitated animals showed a significant decrease in serum potassium levels relative to the baseline value. 
CONCLUSION: Hyperkalemia accompanies hemorrhagic shock and, in addition to providing an early sign of the acute ischemic 
insult severity, may be responsible for cardiac arrest related to hemorrhagic shock.
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INTRODUCTION
Resuscitation of patients in hemorrhagic shock remains 
one of the most challenging aspects of emergency care. 
Uncontrolled bleeding and subsequent circulatory collapse 
account for 40 to 45% of trauma-related deaths. Patients 
with hypovolemia as the primary cause of cardiac arrest 
rarely survive despite heroic resuscitative measures in the 
field, with survival rates of 0 to 3.7%.1
An optimal hemorrhagic shock resuscitation strategy 
during uncontrolled bleeding remains to be determined and 
should be centered around avoidance of cardiac standstill, 
which is considered the primary goal of trauma care.
Although current models for hemorrhagic shock research 
focus on investigation of the pathophysiology of hemorrhage 
and assessment of therapies, the event cascade involved in 
hemorrhagic shock decompensation and cardiac arrest has 
not been fully elucidated.
Hemorrhagic shock is likely to result in electrolyte 
disorders that may play a role in hemorrhagic shock-related 
cardiac standstill. Hemorrhagic shock patients are exposed 
to physiologic processes and life-saving interventions that 
predispose them to hyperkalemia. Despite hyperkalemia is 
recognized as a potentially lethal clinical condition, there 592
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are few studies addressing hyperkalemia in hemorrhagic 
shock. One animal study found that elevated serum 
potassium during prolonged hemorrhagic hypotension was 
correlated with early death.2 Three studies indicate that an 
increase in serum potassium occurs during cardiac arrest 
and prolonged resuscitation.3-5 In the only study assessing 
hyperkalemia during non-crush trauma resuscitation, the 
prevalence of hyperkalemia was 29% and all patients who 
met the criteria for hyperkalemia died.6 In this study, we 
sought to evaluate the effects of different resuscitation 
strategies on the hemodynamics, blood loss and metabolic 
behavior of hemorrhagic shock. Since hyperkalemia was 
frequently observed, we studied the role of potassium in this 
uncontrolled bleeding model.
METHODS
The experiments described here were approved by the 
Institutional Research Ethics Committee and performed in 
29 healthy, 3-4 month old male swine (Agroceres® domestic 
pigs) weighing 27-33 Kg, as a model of hemorrhagic shock 
(HS) after liver trauma. The animals fasted overnight, but had 
free access to water. According to current legal requirements 
and guidelines, animal care was supervised by professional 
veterinarians.
Animals were premedicated with midazolan (0.4 mg/
Kg, im) and ketamine (4 mg/Kg, im). Anesthesia was 
induced with propofol (1-2 mg/Kg, iv) and was maintained 
with propofol and fentanil (0.3 mg, and 0.1 µg/Kg/min, 
respectively, iv). Following oral tracheal intubation, the 
pigs were mechanically ventilated at a volume-controlled 
setting of 15 mL/Kg (Servo-Siemens 900C, Germany) 
with 35% O2. Respiratory frequency was adjusted to 10-15 
breaths/min so as to maintain normocapnia. A pulmonary 
artery catheter was placed by incision into the right internal 
jugular vein and the left femoral artery was cannulated for 
mean arterial pressure monitoring and blood sampling. 
Body core temperature was maintained between 38-39ºC 
throughout the experiment by means of a heating blanket 
and warmed fluids.
Blood pressure was measured using TruWave transducers 
(Edwards Lifesciences, Irvine, USA). ECG and arterial 
pressure were monitored on a Hewlett Packard Merlin Multi-
Parameter monitor. Blood was continuously removed from 
the abdominal cavity using a suction device to determine the 
exact amount of bleeding.
This model was structured in two phases: the hemorrhagic 
shock phase and the interventional phase. The Hemorrhagic 
Shock Phase was begun by means of an incision in the 
right liver lobe (width, 12 cm; depth 2 cm) after anesthesia, 
monitoring and laparotomy. The interventional phase 
was begun when the mean arterial pressure dropped to 40 
mmHg with a blood loss of more than 700 mL. For the 
Interventional Phase, pigs were randomly assigned to five 
groups: (1) the Terli Group (n=6) received an IV bolus of 
2 mg terlipressin; (2) the Control Group (n=5) received an 
equal volume of saline placebo; (3) the HSS Group (n=6) 
received 4 mL/Kg of NaCl 7.5%; (4) the HHES Group (n=6) 
received 4 mL/Kg of NaCl 7.2%/HES 200/0.5 (hypertonic-
hyperoncotic hydroxyethyl starch); (5) the NS Group (n=6) 
received normal saline equivalent to a threefold volume of 
lost blood. No other resuscitation therapy was administered. 
At the end of the interventional phase, the surviving animals 
were followed under another research protocol. Animals with 
a hemorrhagic shock phase time shorter than 10 minutes 
were excluded from the study.
Arterial blood (1 mL; ABL555; Radiometer, Copenhagen, 
Denmark) was sampled and immediately analyzed for 
oxygen saturation, PaO2, PaCO2, potassium, lactate, 
bicarbonate, hemoglobin (Hb), pH, and standard base excess. 
The variables were analyzed at baseline, at the end of the 
shock phase (before any intervention) and at the end of the 
interventional phase.
Statistical analysis was performed using SigmaStat 
software v3.5 (Systat, USA). Data were compared between 
survivors and non-survivors by means of two-way repeated 
measures analysis of variance, followed by Student-
Newmann-Keuls post-hoc test when indicated. Data 
was expressed as mean ± SD. P value less than 0.05 was 
considered as significant.
RESULTS
The survival rate was zero out of five for the Control 
Group and for the HHES Group, two out of six for the NS 
Group, three out of six for the HSS Group, and four out of 
six for the Terli Group. 
Before liver injury, there were no differences between the 
hemodynamic and blood variables among groups. The mean 
overall time of the hemorrhagic shock phase was 20.9 ± 3.9 
min and was not significantly different between groups, or 
between survivors and non-survivors. At the end of the 
hemorrhagic shock phase, the blood loss and hemodynamic 
variables were similar for the five groups. At the end of the 
interventional phase, the intergroup analysis showed similar 
blood loss for the Terli, HSS and Control Groups, and 
significantly more blood loss in the HHES and NS groups 
(Figure 1, p <0.005).
Mean arterial pressure (MAP) five minutes after the 
shock phase was similar in non-survivors and survivors 
(48.7±7.6 mmHg vs. 58.2±12.4 mmHg, p=0.060). At 10, 
20 and 30 minutes into the interventional phase, MAP 593
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progressively decreased in non-survivors, as shown in Figure 
2 (p<0.001).
Serum potassium was significantly increased at the end 
of the shock phase in all groups, before the administration 
of any experimental therapy (3.6±0.3 mmol/L to 5.8±1.4 
mmol/L, p<0.001). The animals that died had significantly 
higher serum potassium levels at the end of the shock phase 
than the surviving animals (6.1±1.6 mmol/L vs. 4.9±0.7 
mmol/L, p=0.017), as shown in Figure 3. All of the animals 
that died within the interventional phase presented a further 
significant increase in the serum potassium levels (6.1±1.6 
mmol/L to 7.4±2.1 mmol/L, p=0.014) preceding cardiac 
arrest. At the end of the interventional phase, the surviving 
animals showed a significant decrease in serum potassium 
levels (4.9±0.7 mmol/L to 3.9±0.6 mmol/L, p<0.001). The 
positive predictive value of potassium levels higher than 5 
mmol/L at shock for mortality was 85.7% and the negative 
predictive value was 70%. 
Arterial pH showed no differences between survivors 
and non-survivors throughout the study (Figure 4). From 
Figure 1 - Blood loss at hemorrhagic phase (filled bars) and at interventional phase (open bars). HSS, hypertonic saline solution; HHES hypertonic-
hyperoncotic hydroxyethyl starch; NS, normal saline. *p<0.005 when compared to Control group.
Figure 2 - Mean arterial pressure before treatment at hemorrhagic phase 
(baseline and shock), and after treatment at 5, 10, 20 and 30 minutes of 
the interventional phase, in survivors (open circles) and non-survivors 
(filled circles). *p<0.001 when compared to non-survivors. †p<0.05 when 
compared to baseline.
Figure 3 - Mean serum potassium before treatment at hemorrhagic phase 
(baseline and shock ), and after treatment at the end of the interventional 
phase, in survivors (open circles) and non-survivors (filled circles). †p<0.001 
when compared to baseline. *p<0.05 when compared to survivors.594
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baseline to shock, there was no variation in arterial pH in 
both survivors (7.45±0.07 to 7.47±0.13) and non-survivors 
(7.47±0.06 to 7.48±0.11).
Base excess was significantly decreased at the end of 
the shock phase in survivors (3.8±2.1 mmol/L to 1.7±3.1 
mmol/L, p=0.02) and non-survivors (4.8±7.9 mmol/L to 
-0.7±3.7 mmol/L, p=0.001), but remained within the normal 
range and there were no differences between survivors 
and non-survivors at shock (1.7±3.1 mmol/L vs. -0.7±3.7 
mmol/L, p=0.098). At the end of the interventional phase, 
base excess exhibited a further significant decrease in 
survivors (1.7±3.1 mmol/L to -4.9±3.0 mmol/L, p<0.001) 
and non-survivors (-0.7±3.7 mmol/L to -17.6±7.5 mmol/L, 
p<0.001). Non-survivors presented significantly lower base 
excess than survivors (p<0.001) (Figure 5).
Arterial lactate exhibited a pattern similar to that 
described for serum potassium, up to a point. It was 
significantly increased in all groups at the end of the shock 
phase, before any experimental therapy (1.6±0.6 mmol/L to 
3.3±1.7 mmol/L, p<0.001). Non-survivors had significantly 
higher arterial lactate levels at the end of the shock phase 
compared to surviving animals (4.1±1.9 mmol/L vs. 2.0±0.7 
mmol/L, p=0.002), as shown in Figure 5. All of the animals 
that died within the interventional phase presented a further 
significant increase in arterial lactate levels (4.1±1.9 mmol/L 
to 12.5±4.5 mmol/L, p<0.001) preceding cardiac arrest. 
However, unlike what was observed for serum potassium, 
arterial lactate continued to rise significantly in the surviving 
animals, until the end of the study (2.0±0.7 mmol/L to 
4.7±2.2 mmol/L, p=0.014). The positive predictive value 
of lactate higher than 2 mmol/L at shock for mortality 
was 62.5% and the negative predictive value was 50% 
(Figure 6).
Figure 4 - Mean arterial pH before treatment at hemorrhagic phase (baseline 
and shock), and after treatment at the end of the interventional phase, in 
survivors (open circles) and non-survivors (filled circles). †p<0.001 when 
compared to baseline. 
Figure 5 - Mean base excess before treatment at hemorrhagic phase (base-
line and shock), and after treatment at the end of the interventional phase, 
in survivors (open circles) and non-survivors (filled circles). †p<0.01 when 
compared to baseline. *p<0.001 when compared to non-survivors.
Figure 6 - Mean serum lactate before treatment at hemorrhagic phase (base-
line and shock), and after treatment at the end of the interventional phase, 
in survivors (open circles) and non-survivors (filled circles). †p<0.05 when 
compared to baseline. *p<0.05 when compared to survivors.595
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DISCUSSION
Main findings of our study were: 1) significant increase 
in serum potassium occurred before any treatment in all 
animals; 2) this increase in potassium was not related to 
arterial acidemia, suggesting rising serum potassium occurs 
early and accompanies the onset of HS; 3) the rate of rise 
in serum potassium and its levels before any treatment were 
higher in non-survivors, suggesting that potassium level 
is an early sign of acute ischemic insult severity and may 
early distinguish potential survivors from non-survivors; 
4) at the end of study the animals that died presented a 
further increase in the potassium levels while the surviving 
animals showed a decrease near to baseline, suggesting that 
potassium level may be a potential marker of metabolic 
failure to monitoring the therapeutic strategies in HS.
A significant increase in serum potassium was observed 
in this animal model of hemorrhagic shock before the 
administration of any treatment. The mean potassium 
value at shock was above the upper range of normal. When 
comparing survivors to non-survivors, the animals that died 
presented serum potassium levels that were 24.5% higher 
than non-survivors at shock, before any treatment. This 
increase in potassium was not related to arterial acidemia. 
Although a decrease in base excess occurred from baseline 
to shock, it remained within the normal range and there 
was no difference between survivors and non-survivors. 
At five minutes into the interventional phase, mean arterial 
pressure was unable to differentiate the surviving animals 
from the non-surviving ones. All of the animals that died 
presented a further significant increase in the potassium 
levels preceding cardiac arrest, while the surviving animals 
showed a significant decrease to near baseline. 
Serum lactate levels significantly increased at shock 
before the administration of any experimental therapy. 
Although lactate levels were higher in non-survivors at 
shock, lactate levels presented by non-survivors at shock 
were similar to those presented by survivors at the end of the 
experiment. The continued rise in serum lactate presented by 
survivors is probably the result of the washout of products 
of anaerobic metabolism during reperfusion. This post-
resuscitation lactic acidemia in survivors was accompanied 
by a decrease in serum potassium. 
Hemorrhagic shock is a global ischemic insult. Within 
seconds of the onset of ischemia, oxidative phosphorylation 
is inhibited and inefficient anaerobic metabolism becomes 
the primary means of high energy phosphate production. 
Once the alternative energy sources are exhausted, the 
disruption of the energetic status of the cell leads to 
extracellular K accumulation.7 Interstitial hyperkalemia 
during hemorrhage has previously been demonstrated.8-10 
Three mechanisms are recognized as contributing to 
disruption of potassium homeostasis during ischemia: 1) 
increased cellular K efflux, 2) decreased cellular K influx and 
3) shrinkage of extracellular space.7,11 Despite experimental 
evidence suggested that the Na-K pump is inhibited during 
ischemia and thus is a mechanism contributing to the 
decrease K influx7,12, the ATP-sensitive K (KATP) channels 
activation are thought to be the primary mechanism through 
which K efflux may increase during ischemia and contribute 
to the rise in potassium.11,13,14 There is an ongoing debate on 
the literature about the role of KATP channels in hemorrhagic 
shock decompensation.15-17 However, based on our findings, 
we can hypothesize that KATP channels activation would 
occur earlier, by the time of HS onset.
Despite hyperkalemia is recognized as a potentially 
lethal clinical condition, there are few studies addressing 
hyperkalemia in hemorrhagic shock. The silent characteristic 
of hyperkalemia, which may be not recognized in the 
patient who dies early during resuscitation, as well its 
transient behavior, in those who undergo a successful 
resuscitation, may be responsible for the scarce attention to 
this complication.
Torres et al.2 found that elevated serum potassium during 
prolonged hemorrhagic hypotension in rats was correlated 
with mortality and may explain the sudden death in animals 
in their experiment. 
Perkins et al,6 in a prospective observational analysis of 
131 patients during the initial 12 hours after admission for 
non-crush trauma, found a surprisingly high prevalence of 
hyperkalemia (29%) and all patients who met the criteria 
for hyperkalemia died. In this original report, independent 
risk factors for hyperkalemia were plasma potassium 
level at admission ≥ 4 mmol/L and transfusion of cell- or 
plasma-based products. Acidosis did not contribute to 
hyperkalemia. 
The most prominent effect of hyperkalemia is on the 
myocardium. Decreases in resting membrane potential 
reduce myocardial conduction velocity and increase the rate 
of polarization. A slowed conduction velocity (increased 
PR interval and widened QRS complex), especially in the 
presence of increased repolarization rates (peaked T waves), 
increases the chance of ventricular fibrillation and cardiac 
standstill.
In their assessment of hyperkalemia and hypocalcemia 
during cardiac arrest in an animal model of ventricular 
fibrillation, Niemann et al.5 found that hyperkalemia and 
hypocalcemia occurred during prolonged resuscitative 
efforts in unsuccessfully resuscitated animals. The increase 
in serum potassium observed in their study, in agreement 
with our data, was not related to acidemia and successfully 
resuscitated animals did not demonstrate these electrolyte 596
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changes. The authors hypothesized that the electrolyte 
changes may play a role in refractory cardiac arrest.
Martin et al.3,4 showed that an increase in serum 
potassium occurs during cardiac arrest and prolonged 
cardiopulmonary resuscitation in an animal model and in 
patients.
Rather than being only a sign of acute ischemic insult 
severity, hyperkalemia is a life-threatening condition 
that requires emergency treatment, mainly before blood 
transfusion, which is a cornerstone in the treatment of 
hemorrhagic shock. Brown et al.18 retrospectively studied 
138 cardiac arrests in a pediatric population, comparing 
patients who received a rapid blood transfusion with those 
who did not, found that the during cardiac arrest mean serum 
potassium in the non-transfused group versus the transfused 
group was 5.6 mmol/L versus 8.2 mmol/L. Data from their 
study demonstrated that hyperkalemia during cardiac arrest 
could be explained as a consequence of rapid RBC transfusion 
during hypovolemic-reduced cardiac output states.
A number of reports describing transfusion-related 
hyperkalemia and cardiac arrest have been published.19-22 
Smith et al.22 in a recent retrospective review, identified 16 
patients in whom stored red blood cell (RBC) transfusion-
associated hyperkalemia was found to be a significant 
factor in precipitating intraoperative cardiac arrest. The 
main finding of the study was that transfusion-associated 
hyperkalemic cardiac arrest may develop with rapid RBC 
administration even with modest transfusion volume. Banked 
RBC potassium concentration may present levels up to 35 
mmol/L after 21 storage days.23
The most fundamental limitation of this study is that it is 
involved in an animal model, and so the way it is related to 
the complexity of real human injuries is unclear. The study 
was not addressed to evaluate the serum potassium behavior 
patterns during hemorrhagic shock and we were not able 
to analyze serum ionized calcium. The heterogeneity of 
the tested strategies recommends caution in the analysis 
of the registered results after the various therapeutic 
interventions.
If these results could be translated to human beings, 
they may open a new vista into the resuscitative strategy for 
hemorrhagic shock. Current animal models used to evaluate 
different resuscitative strategies focused on hemodynamic 
data will need an urgent review and our clinical resuscitative 
protocols will need to incorporate identification and 
prophylactic management of high-risk patients.
CONCLUSION
To  the  best  of  our  knowledge,  this  is  the  first 
demonstration  that,  during  uncontrolled  bleeding, 
hyperkalemia unrelated to arterial acidemia accompanies the 
onset of hemorrhagic shock and relates to mortality. Rising 
potassium may be one early sign of acute ischemic insult 
severity and could conceivably help us clarify the frontier of 
hemorrhagic shock refractoriness.
Studies are needed to evaluate the mechanisms and the 
clinical impact of rising potassium in hemorrhagic shock. 
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